Table 1.
Characteristics of the Study Participants
| |
|
Early |
Intermediate |
Late |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Participants | HLA type | Age (months) | VLa | CD4%/Abs | Age (months) | VL | CD4%/Abs | Age (months) | VL | CD4%/Abs |
| Arm A (n=6) | ||||||||||
| Slow-progressors | ||||||||||
| A-517C | A3002/6802 B1510/4201 Cw03/1701 |
4 | 5,620,000 | 25/2671 | 18 | >750000 | 27/1745 | 48 | 40,535 | 36/1716 |
| A-133C | A6801/7408 B5802/8101 Cw04/0602 |
6 | 180,000 | 38/2884 | 16 | 40,600 | 32/2130 | 55 | 18,300 | 32/1612 |
| Rapid-progressors | ||||||||||
| A-298C | A29/6802 B13/1401 Cw06/08 |
6 | 318,000 | 11/831 | 14b | 1,050 | 17/1716 | 33 | <50 | 23/2220 |
| A-562C | A0205/3002 B1402/5801 Cw07/0802 |
6 | 11,860 | 10/581 | 13 | 519 | 29/2316 | 27 | <50 | 27/2460 |
| A-458C | A4301/6802 B1503/1510 Cw03/18 |
3 | 583,000 | 17/1198 | 20 | <50 | 43/2333 | 29 | <50 | 48/2653 |
| A-447C | A03/6802 B1401/4701 Cw0602/0802 |
2 | 7,820,000 | 25/1206 | 20 | 717 | 33/1709 | 25 | <50 | 34/1617 |
| Arm B (n=9) | ||||||||||
| Slow-progressors | ||||||||||
| B-114C | A0301/24 B07/08 Cw07/07 |
N/Ac | N/A | N/A | 23 | 249,000 | 24/1761 | 46 | 11,800 | 19/702 |
| B-380C | A2301/6802 B1510/1510 Cw03/08 |
5 | 101 | 40/2214 | 20 | 65,200 | 31/1352 | 38 | 373,000 | 30/790 |
| B-559C | A2301/6802 B0801/5801 Cw07/07 |
4 | <50 | 53/2433 | 21 | 973,000 | 25/1310 | 38 | 356,000 | 21/1275 |
| B-586C | A0101/6802 B1510/8101 Cw08/1801 |
2 | 387 | 38/2620 | 15 | 137,000 | 30/2896 | 42 | >750000 | 18/922 |
| B-021C | A0205/29 B4201/44 Cw0202/1701 |
5 | <50 | 33/1587 | 16 | >750000 | 33/2179 | 38 | 99,895 | 24/1435 |
| Rapid-progressors | ||||||||||
| B-001C | A0101/3001 B4201/8101 Cwl7/1801 |
4 | <50 | 54/3137 | 21 | 236,000 | 25/1898 | 47 | <50 | 29/1409 |
| B-222C | A29/6802 B0702/1302 Cw0602/07 |
N/A | N/A | N/A | 13 | 56,900 | 11/233 | N/A | N/A | NA |
| B-675C | A6601/6802 B1510/39 Cw03/12 |
4 | 1,290 | 47/2194 | 16 | 714,000 | 14/1540 | 37 | <50 | 37/2666 |
| B-732C | A3002/6602 B4201/45 Cwl601/1701 |
3 | 2,000 | 22/1873 | 15 | 654,000 | 17/1032 | N/A | N/A | NA |
a
Plasma HIV RNA measurement; dilutions for quantification of high viral load (VL) >750,000 was done for some and not all patients due to inadequate sample availability.
b
Terms in bold indicate time on ART, applicable to Arm A rapid-progressor children at the intermediate and late time points; all Arm B children at the early time point and Arm B rapid-progressors at the late time point.
c
N/A, sample not available for measurement.